161 related articles for article (PubMed ID: 33010478)
1. MELK/MPK38 in cancer: from mechanistic aspects to therapeutic strategies.
Thangaraj K; Ponnusamy L; Natarajan SR; Manoharan R
Drug Discov Today; 2020 Dec; 25(12):2161-2173. PubMed ID: 33010478
[TBL] [Abstract][Full Text] [Related]
2. The crystal structure of MPK38 in complex with OTSSP167, an orally administrative MELK selective inhibitor.
Cho YS; Kang Y; Kim K; Cha YJ; Cho HS
Biochem Biophys Res Commun; 2014 Apr; 447(1):7-11. PubMed ID: 24657156
[TBL] [Abstract][Full Text] [Related]
3. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
5. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
[TBL] [Abstract][Full Text] [Related]
6. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.
Ikeda Y; Sato S; Yabuno A; Shintani D; Ogasawara A; Miwa M; Zewde M; Miyamoto T; Fujiwara K; Nakamura Y; Hasegawa K
J Gynecol Oncol; 2020 Nov; 31(6):e93. PubMed ID: 33078598
[TBL] [Abstract][Full Text] [Related]
7. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
Chlenski A; Park C; Dobratic M; Salwen HR; Budke B; Park JH; Miller R; Applebaum MA; Wilkinson E; Nakamura Y; Connell PP; Cohn SL
Mol Cancer Ther; 2019 Mar; 18(3):507-516. PubMed ID: 30674566
[TBL] [Abstract][Full Text] [Related]
8. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2016 Apr; 7(14):18171-82. PubMed ID: 26918358
[TBL] [Abstract][Full Text] [Related]
9. Thr55 phosphorylation of p21 by MPK38/MELK ameliorates defects in glucose, lipid, and energy metabolism in diet-induced obese mice.
Seong HA; Ha H
Cell Death Dis; 2019 May; 10(6):380. PubMed ID: 31097688
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
[TBL] [Abstract][Full Text] [Related]
11. Maternal embryonic leucine zipper kinase (MELK): a novel regulator in cell cycle control, embryonic development, and cancer.
Jiang P; Zhang D
Int J Mol Sci; 2013 Oct; 14(11):21551-60. PubMed ID: 24185907
[TBL] [Abstract][Full Text] [Related]
12. DAXX ameliorates metabolic dysfunction in mice with diet-induced obesity by activating the AMP-activated protein kinase-related kinase MPK38/MELK.
Seong HA; Manoharan R; Ha H
Biochem Biophys Res Commun; 2021 Oct; 572():164-170. PubMed ID: 34365141
[TBL] [Abstract][Full Text] [Related]
13. A crucial role for the phosphorylation of STRAP at Ser(188) by MPK38 in STRAP-dependent cell death through ASK1, TGF-β, p53, and PI3K/PDK1 signaling pathways.
Seong HA; Manoharan R; Ha H
Cell Cycle; 2014; 13(21):3357-74. PubMed ID: 25485581
[TBL] [Abstract][Full Text] [Related]
14. Arrestin-3 interaction with maternal embryonic leucine-zipper kinase.
Perry NA; Fialkowski KP; Kaoud TS; Kaya AI; Chen AL; Taliaferro JM; Gurevich VV; Dalby KN; Iverson TM
Cell Signal; 2019 Nov; 63():109366. PubMed ID: 31352007
[TBL] [Abstract][Full Text] [Related]
15. Structural insight into maternal embryonic leucine zipper kinase (MELK) conformation and inhibition toward structure-based drug design.
Canevari G; Re Depaolini S; Cucchi U; Bertrand JA; Casale E; Perrera C; Forte B; Carpinelli P; Felder ER
Biochemistry; 2013 Sep; 52(37):6380-7. PubMed ID: 23914841
[TBL] [Abstract][Full Text] [Related]
16. The structures of the kinase domain and UBA domain of MPK38 suggest the activation mechanism for kinase activity.
Cho YS; Yoo J; Park S; Cho HS
Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):514-21. PubMed ID: 24531485
[TBL] [Abstract][Full Text] [Related]
17. Structural classification of MELK inhibitors and prospects for the treatment of tumor resistance: A review.
Ren L; Guo JS; Li YH; Dong G; Li XY
Biomed Pharmacother; 2022 Dec; 156():113965. PubMed ID: 36411642
[TBL] [Abstract][Full Text] [Related]
18. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Lin ML; Park JH; Nishidate T; Nakamura Y; Katagiri T
Breast Cancer Res; 2007; 9(1):R17. PubMed ID: 17280616
[TBL] [Abstract][Full Text] [Related]
19. Structure-based discovery of new maternal embryonic leucine zipper kinase inhibitors.
Zhou S; Li GB; Luo L; Zhong L; Chen K; Li H; Jiang XJ; Fu Q; Long X; Bao JK
Org Biomol Chem; 2018 Feb; 16(9):1489-1495. PubMed ID: 29411820
[TBL] [Abstract][Full Text] [Related]
20. Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma.
Maes A; Maes K; Vlummens P; De Raeve H; Devin J; Szablewski V; De Veirman K; Menu E; Moreaux J; Vanderkerken K; De Bruyne E
Blood Cancer J; 2019 Nov; 9(12):87. PubMed ID: 31740676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
